Sonoma Pharmaceuticals (NASDAQ:SNOA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. “
Several other analysts have also commented on SNOA. Maxim Group raised their target price on Sonoma Pharmaceuticals from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Benchmark started coverage on Sonoma Pharmaceuticals in a report on Thursday, December 28th. They set a “speculative buy” rating and a $10.00 target price on the stock.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.